Puma Biotechnology Reports Results of PB272 (neratinib) in P-III NALA Trial for Patients with 2L+ HER2+ Metastatic Breast Cancer #ASCO2019
Why Puma Biotechnology, Inc. Stock Crashed 37% in March | Fox Business
Puma Biotech plunges on drug side effects
Puma Biotechnology
Why Puma Biotechnology (PBYI) Stock Is Surging Today - TheStreet
PumaBiotech on Twitter: "At Puma Biotechnology, our focus is on helping #cancer patients. We understand the #HER2 #breastcancer population faces challenges well beyond the point of care. We strive to empower patients